Status: Baseline only
Increase the proportion of Medicare beneficiaries with chronic kidney disease who receive medical evaluation with serum creatinine, lipids, and urine albumin tests
Baseline: 34.0 percent of Medicare beneficiaries aged 65 years and over with chronic kidney disease received medical evaluation with serum creatinine, lipids, and urine albumin tests in 2016
Target: 46.7 percent
Data Source: United States Renal Data System (USRDS), NIH/NIDDK
Testing for serum creatinine, lipids, and urine albumin is important in people with chronic kidney disease (CKD). Health care providers can use these tests to see how well kidneys are working, find out if CKD has gotten worse, and decide the best course of treatment. Research has shown that using these 3 tests can help prevent or delay end-stage kidney disease.
Workgroup: Chronic Kidney Disease Workgroup